Overview

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborators:
Eli Lilly and Company
Genentech, Inc.
Treatments:
Bevacizumab
Carboplatin
Gemcitabine